AinnocenceSep 4 2024

Ainnocence Inc., a leader in AI-driven biotech solutions, is proud to announce the launch of CellulaAI™, an innovative AI engine designed to transform the landscape of CAR-T therapy. By harnessing the power of artificial intelligence, CellulaAI™ optimizes every aspect of the CAR-T design and production process, paving the way for safer, more effective, and personalized cancer treatments worldwide.

CellulaAI™ is built on a robust framework that enhances the efficacy, safety, and scalability of CAR-T therapies. This next-generation AI system integrates advanced computational methods to streamline and accelerate key processes in the development of CAR-T cells, offering unparalleled precision and insight at every stage.

Key Features of CellulaAI™:

* Target Antigen Identification: Accurately identifies the most effective antigens to target cancer cells with high specificity.

* ScFv Design and Optimization: Engineers single-chain variable fragments (ScFv) for superior binding affinity and stability.

* Costimulatory Domains Selection: Chooses the optimal costimulatory domains to enhance T-cell activation and persistence.

* Off-target and Immunogenicity Screening: Performs comprehensive in silico screenings to minimize off-target effects and immunogenicity risks.

* In Silico Testing and Validation: Simulates and validates the efficacy and safety of CAR-T designs before clinical trials.

Revolutionizing CAR-T Therapy:

CellulaAI™ represents a significant breakthrough in the quest for more personalized and effective cancer treatments. By optimizing the design and production of CAR-T cells, this AI engine not only improves patient outcomes but also accelerates the development pipeline, reducing costs and time to market.

One of the key advantages of CellulaAI™ is its unparalleled ability to optimize binding specificity against a broad group of antigens. This capability surpasses what other computational engines can achieve, making it possible to target a wider array of cancer cells with greater precision. This specificity not only enhances the effectiveness of the therapy but also reduces potential side effects, offering a safer treatment option for patients.

"We believe that CellulaAI™ is a game-changer in the field of CAR-T therapy," said Lurong Pan, CEO of Ainnocence. "Our AI-driven approach brings a new level of precision and efficiency to cell programming, ultimately offering patients safer and more personalized treatment options."

Source:

Ainnocence